Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease

British Journal of Haematology

Volumn 113, Issue 1, 2001, Pages 100-102

  Fontana, S ^a,b   Gerritsen, H E ^a   Kremer Hovinga, J ^a   Furlan, M ^a   Lammle B ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Microangiopathy; Neoplasia; Proteolysis; Von Willebrand factor

Indexed keywords

PROTEINASE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AGED; ANEMIA, HEMOLYTIC; AUTOANTIGENS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOBLOTTING; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PROSTATIC NEOPLASMS; VON WILLEBRAND FACTOR;

EID: 0035003933     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02704.x     Document Type: Article

References (12)

1. Carcinoma-associated hemolytic-uremic syndrome: A complication of mitomycin C chemotherapy
2. Thrombotic microangiopathy as complication of high-dose chemotherapy for breast cancer
3. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
4. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura
5. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
6. Assay of von Willebrand factor (vWF) -cleaving protease based on decreased collagen binding affinity of degraded vWF. A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)
7. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient
8. Thrombotic thrombocytopenic purpura: Understanding a disease no longer rare
9. A toxic interaction between mitomycin C and tamoxifen causing the hemolytic uremic syndrome
10. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: An explanation for platelet aggregation in thrombotic thrombocytopenic purpura
11. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies
12. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura